Literature DB >> 3788805

Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries.

M N Papanicolaou, R M Califf, M A Hlatky, R A McKinnis, F E Harrell, D B Mark, B McCants, R A Rosati, K L Lee, D B Pryor.   

Abstract

The clinical presentation and prognosis of 1,977 consecutive patients with normal coronary arteries or "insignificant" coronary artery disease (CAD) (no major epicardial artery with 75% or more luminal diameter narrowing) were examined. Compared with patients with significant CAD, these patients had a lower frequency of traditional cardiac risk factors and abnormalities on the rest and exercise electrocardiogram. Cardiac survival was 99% at 5 years of follow-up and 98% at 10 years for patients with normal or insignificantly narrowed coronary arteries. Patients with normal coronary arteries differed from those with insignificant CAD in their myocardial infarction free survival rate: 99% at 5 years and 98% at 10 years for patients with normal coronary arteries, compared with 97% at 5 years and 90% at 10 years for patients with insignificant CAD. A strong relation occurred between the amount of insignificant CAD and follow-up cardiac events (chi 2 = 21.5, p less than 0.0001). Cardiac risk factors were statistically related to the risk of follow-up cardiovascular events when considered alone (chi 2 = 4.93, p = 0.026), but this relation lost significance after adjusting for the effect of coronary anatomy. Patients in both groups continued to have cardiac symptoms that resulted in frequent hospitalizations, medication use and job disability. Almost 50% in any given year of follow-up could not perform activities of high metabolic equivalent requirement and 70% had continuing symptoms of chest discomfort. Although these patients are at low risk of death, many remain functionally impaired for years.

Entities:  

Mesh:

Year:  1986        PMID: 3788805     DOI: 10.1016/0002-9149(86)90378-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  34 in total

1.  Theodore E. Woodward Award. Ischemic heart disease in women: the role of coronary microvascular dysfunction.

Authors:  C J Pepine
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

2.  Normal coronary angiograms: financial victory from the brink of clinical defeat?

Authors:  B Keavney; Y M Haider; A J McCance; J D Skehan
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

3.  Syndrome X: radionuclide studies of myocardial perfusion in patients with chest pain and normal coronary arteriograms.

Authors:  S D Rosen; P G Camici
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms.

Authors:  Richard O Cannon
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

5.  Emotional distress among males with "syndrome X".

Authors:  M W Ketterer; J Brymer; K Rhoads; P Kraft; L Kenyon; B Foley; W R Lovallo; C J Voight
Journal:  J Behav Med       Date:  1996-10

Review 6.  Cardiac Syndrome X: update 2014.

Authors:  Shilpa Agrawal; Puja K Mehta; C Noel Bairey Merz
Journal:  Cardiol Clin       Date:  2014-06-02       Impact factor: 2.213

Review 7.  Syndrome X--angina and normal coronary angiography.

Authors:  A Chauhan
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

Review 8.  Chest pain and angiographically normal coronary arteries. Implications for treatment.

Authors:  V Mukerji; B D Beitman; M A Alpert
Journal:  Tex Heart Inst J       Date:  1993

9.  Clinical presentation and functional prognosis in syndrome X.

Authors:  A Chauhan; P A Mullins; S I Thuraisingham; M C Petch; P M Schofield
Journal:  Br Heart J       Date:  1993-10

10.  Coronary autoregulation is abnormal in syndrome X: insights using myocardial contrast echocardiography.

Authors:  Diana Rinkevich; Todd Belcik; Nandita C Gupta; Elizabeth Cannard; Nabil J Alkayed; Sanjiv Kaul
Journal:  J Am Soc Echocardiogr       Date:  2013-01-11       Impact factor: 5.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.